Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danuglipron Multiple Dose PK Study in Overweight/Obese Adults
NCT06568731Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of danuglipron in obesity, sponsored by Pfizer. Primary endpoints: Steady-state area under the concentration-time profile from time zero to 24 hours, Steady-state maximum observed concentration and 1 more. Started Aug 2024; status: completed.
02
Drugs
danuglipron
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06568731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06568731.